Euro Startups
Sweden-Based LegalTech Startup Lightbringer Raises $10M to Expand AI-Powered Patent Platform
The funding will support product development and U.S. expansion as Lightbringer looks to simplify intellectual property protection for startups and deeptech companies.
Lightbringer, a Sweden-based legaltech startup, has raised $10 million in Series A funding to accelerate the development of its AI-powered patent platform and expand its presence in the United States. The round was co-led by London-based 6 Degrees Capital and Amsterdam-based Newion.
As part of the investment, Thomas Olszewski, Partner at 6 Degrees Capital, and Dorus Olgers, Partner at Newion, have joined the company’s board of directors.
Founded in 2023, Lightbringer is building a technology-driven platform designed to make patent protection faster, more affordable, and more accessible for startups and small and medium-sized enterprises. The company combines intellectual property strategy, patent filing, and portfolio management within a single platform, reducing reliance on traditional legal workflows.
Modernizing the Patent Filing Process
Securing patents remains a complex and resource-intensive process for many businesses, particularly early-stage companies operating in highly technical industries.
Traditional patent filing often requires extensive collaboration between engineering teams, legal advisers, and external law firms, resulting in lengthy timelines and significant costs. The challenge is further compounded by a global shortage of patent attorneys with expertise in specialized technical fields.
Lightbringer aims to address these inefficiencies through a platform that combines agentic AI with oversight from experienced patent professionals. By automating large parts of the patent preparation and filing process, the company says it can reduce filing timelines from approximately two months to just a few days.
The platform also operates on a fixed-price subscription model, offering companies greater predictability compared to traditional hourly billing structures commonly used in intellectual property services.
Building an AI-Native Intellectual Property Platform
While artificial intelligence is increasingly being adopted across the legal sector, many patent-focused AI tools are designed primarily to improve productivity for lawyers and patent professionals.
Lightbringer has taken a different approach by developing an AI-native platform that directly manages significant portions of the patent workflow on behalf of clients.
The company believes this model can help innovative businesses secure intellectual property rights more efficiently, allowing them to focus on product development and commercialization rather than administrative and legal complexities.
Its platform supports intellectual property strategy, patent drafting, filing management, and portfolio oversight, creating a unified solution for companies seeking to build and protect innovation assets.
Expanding in the United States
The newly raised capital will be used to strengthen Lightbringer’s position in the growing intellectual property technology market while supporting its expansion into the United States.
The company sees significant opportunities among startups and deeptech businesses that require patent protection but often lack the resources or expertise to navigate traditional legal processes efficiently.
Alongside its geographic expansion, Lightbringer plans to continue enhancing its AI-powered platform and developing additional capabilities tailored to technology-driven businesses.
The latest investment reflects growing investor interest in legal technology platforms that use artificial intelligence to automate specialized professional services. As innovation cycles accelerate and intellectual property becomes increasingly important for emerging companies, demand for faster and more accessible patent solutions continues to rise.
With fresh funding, new board-level support, and ambitions to expand internationally, Lightbringer is positioning itself to reshape how startups and SMEs secure and manage intellectual property. The company believes its combination of AI automation and expert oversight can help make patent protection more efficient, affordable, and scalable for the next generation of innovators.
Euro Startups
Netherlands-Based Startup Mondrio Raises $3.75M Funding Led by Heartcore Capital to Expand AI-Powered B2B Pricing Automation Platform
The investment will support the development of its AI-powered B2B pricing platform, expansion of its engineering and pricing teams, and commercial growth across the United States and Europe.
Mondrio, a Netherlands-US startup developing AI-powered pricing tools for businesses, has raised $3.75 million in a funding round led by Heartcore Capital. Pretiosum VC, Hersir Ventures, Cambrena Capital and Momo VC also participated, alongside angel investors with experience in pricing, configure-price-quote (CPQ) software, AI and payments.
Founded in 2026 by Gregor Biljardt and Joep van den Nieuwenhoff, Mondrio operates across Amsterdam and San Francisco. Its platform combines pricing intelligence, AI agents and workflow automation to help businesses analyse customer behaviour, product changes, competitor information and market signals.
Pricing Strategy and Deal Execution
Mondrio’s platform has two core products. Pricing Studio helps businesses develop and refine pricing strategies, including product packaging, pricing models and price levels. It draws on market and customer data to help companies assess whether their pricing remains aligned with changing conditions.
Deal Engine applies pricing guidance to individual transactions. It supports sales teams with quotes, discounts, negotiations and contract renewals, and automates quoting and approval workflows within parameters set by each business. Mondrio aims to connect strategic pricing decisions with sales execution, allowing information from completed deals to inform future pricing.
The company’s AI agents are designed to analyse both quantitative data, such as customer behaviour and product performance, and qualitative inputs, including customer conversations and market feedback. Mondrio says the agents will help businesses identify pricing opportunities and support actions through commercial workflows. It has not disclosed how autonomously the agents currently operate or what controls govern their decisions.
Funding to Support Expansion
Mondrio plans to use the funding to expand its AI, engineering and pricing teams, improve its agent capabilities and grow its commercial presence in the United States and Europe. It also intends to extend its platform beyond B2B technology companies into manufacturing and professional services.
The startup is targeting pricing challenges that can arise as companies introduce AI-powered products. Unlike conventional software, AI services can incur variable computing costs with each customer interaction, making it harder to set prices that reflect usage and maintain profitability. Mondrio aims to help businesses adapt pricing as products, costs and customer expectations change.
The company has not disclosed its valuation, the formal stage of the round, its customer count or revenue. It also did not provide a timeline for entering new industries or specific targets for hiring and expansion.
Euro Startups
UK FinTech Griffin Raises $20M Series B Led by Octagon Partners to Expand Banking Infrastructure Platform at $100M+ Valuation
The investment values the company at more than $100 million and will support the expansion of its banking-as-a-service platform, including card issuing and stablecoin services.
Griffin operates as a licensed UK bank and provides banking-as-a-service (BaaS) infrastructure that enables FinTech companies and other businesses to integrate banking products into their own applications and platforms. Its technology supports bank accounts, payments, customer identity verification and anti-money laundering processes, allowing companies to offer financial services without obtaining their own banking licences for the underlying services provided by Griffin.
The company plans to use the new capital to expand its banking product portfolio, particularly through the development of card issuing and stablecoin-related services. The funding is also expected to support Griffin’s efforts to achieve full-year profitability.
Led by CEO and Co-founder David Jarvis, a former Airbnb executive, Griffin reports that more than 80 companies are building products using its infrastructure, including Uber. The company has expanded its customer base since launching as a licensed bank approximately two years ago.
Griffin Secures $20M Series B Funding From Octagon Partners and Existing Investors
Griffin’s $20 million Series B financing round was led by Octagon Partners, with participation from Notion Capital, A+ Ventures, Nordic Ninja, Breega and other existing investors.
The investment increases Griffin’s total capital raised to approximately $95 million and values the company at more than $100 million.
The new funding will support the expansion of Griffin’s banking infrastructure, enabling the company to introduce additional financial products while strengthening its existing services.
Card issuing and stablecoin-related capabilities are among the company’s main development priorities. These products are intended to complement its existing bank account and payment infrastructure and broaden the services available to businesses building financial applications.
Griffin also plans to use the investment to support its progress toward full-year profitability, although it has not disclosed a specific timeline for achieving that milestone.
The company has not revealed its exact post-funding valuation, the ownership stakes acquired by investors or the individual investment amounts contributed by participants in the round.
Griffin Provides Banking-as-a-Service Infrastructure Through UK Banking Licence
Griffin operates a banking-as-a-service platform that enables companies to embed banking capabilities directly into their digital products.
The company holds a UK banking licence, allowing it to provide regulated banking infrastructure rather than relying entirely on third-party banking partners.
Through Griffin’s technology, FinTech businesses and other organisations can integrate bank accounts and payment services into their own applications without establishing a bank independently.
This model allows businesses to focus on developing customer-facing products while using Griffin’s underlying infrastructure to deliver banking functionality.
The platform also provides services related to know-your-customer (KYC) verification and anti-money laundering (AML), helping companies manage important components of regulated financial operations.
Although Griffin’s banking licence enables businesses to access regulated banking services, customers may still have their own compliance or licensing obligations depending on the financial activities they undertake.
Griffin Supports Bank Accounts, Payments and Financial Compliance
Griffin’s platform provides the infrastructure required for businesses to incorporate banking products into their existing services.
Its capabilities include bank accounts and payments, allowing companies to develop financial applications without building the underlying banking systems themselves.
The platform also supports KYC and AML processes, which are important for verifying customer identities and managing risks associated with financial crime.
By combining banking infrastructure with compliance-related services, Griffin aims to reduce the complexity involved in launching and operating financial products.
The company’s technology can be used by FinTech startups and established businesses seeking to offer embedded financial services through their own platforms.
Griffin has not disclosed the total number of active bank accounts supported by its infrastructure, its payment processing volumes or the revenue generated by its banking services.
Griffin Reports Over 80 Companies Building on Its Infrastructure, Including Uber
Griffin reports that more than 80 companies are building products using its banking infrastructure, including Uber.
The figure reflects adoption of its platform since the company launched as a licensed bank approximately two years ago.
Griffin’s technology allows businesses to incorporate banking functionality into their products without developing and maintaining the underlying regulated infrastructure independently.
For companies offering embedded financial services, access to an established banking platform can simplify technical integration and reduce the operational requirements associated with building financial products.
However, Griffin has not disclosed how many of its 80-plus customers have launched live banking services, how many remain in development or the proportion generating recurring revenue.
The company has also not provided details about the specific banking services used by Uber.
Griffin Plans to Expand Into Card Issuing and Stablecoin Services
A major priority for Griffin following its Series B funding round is expanding its product portfolio beyond existing banking and payment capabilities.
The company plans to develop card issuing services, which would allow businesses to integrate payment card functionality into their own financial products.
Card issuing could complement Griffin’s existing bank account and payment infrastructure, providing customers with access to additional financial services through the same platform.
Griffin also intends to introduce stablecoin-related services as part of its broader infrastructure strategy.
Stablecoins are digital assets designed to maintain a relatively stable value, typically by reference to a fiat currency. They can be used in certain payment and settlement applications, although their use involves regulatory and operational considerations.
Griffin has not disclosed whether its planned stablecoin offering will involve issuance, payments, custody or infrastructure services for third-party providers.
The company has also not announced launch dates for its card issuing or stablecoin products.
Griffin Targets Full-Year Profitability Following $20M Investment
In addition to expanding its services, Griffin intends to use the new funding to support its financial performance as it works toward achieving full-year profitability.
The company has not disclosed its current revenue, operating losses or expected date for reaching profitability.
Its growth strategy involves increasing adoption of its banking infrastructure and expanding the range of services available to existing and prospective customers.
Additional products such as card issuing and stablecoin-related services could create new commercial opportunities, although their financial contribution will depend on customer demand, implementation and regulatory requirements.
As a licensed bank, Griffin must also manage the regulatory and operational responsibilities associated with providing financial services.
The latest investment will provide additional capital as the company develops its infrastructure and works toward sustainable financial performance.
Griffin CEO David Jarvis Highlights Growth Opportunities in Banking Infrastructure
David Jarvis, CEO and Co-founder of Griffin, said the new funding will allow the company to accelerate the development of additional banking products.
“This round lets us go further: cards and stablecoins are the natural next layer for our infrastructure,” Jarvis said.
He also welcomed Octagon Partners as the lead investor and highlighted continued support from Griffin’s existing investors.
Jarvis previously worked at Airbnb before co-founding Griffin, which has developed a licensed banking infrastructure platform serving FinTech companies and other businesses.
Under his leadership, the company has expanded its customer base and raised approximately $95 million in cumulative funding.
The Series B investment will support Griffin’s next phase of product development as it seeks to broaden its banking-as-a-service offering.
Griffin Raises Total Funding to $95M as Valuation Surpasses $100M
Griffin’s $20 million Series B funding round marks another stage in the London-based company’s expansion within the banking infrastructure market.
Led by Octagon Partners, with participation from Notion Capital, A+ Ventures, Nordic Ninja, Breega and existing investors, the financing increases Griffin’s cumulative funding to approximately $95 million and values the company at more than $100 million.
Griffin provides licensed banking-as-a-service infrastructure that enables businesses to integrate bank accounts, payments and compliance-related capabilities into their digital platforms.
The company reports that more than 80 businesses, including Uber, are building on its technology following its launch as a licensed UK bank approximately two years ago.
With the latest investment, Griffin plans to expand into card issuing and stablecoin-related services while working toward achieving full-year profitability.
Euro Startups
Lithuanian AI-powered Biotechnology Company Biomatter Raises $18M Series A Led by Astanor to Accelerate Custom Enzyme Development
The investment will support the development of a new enzyme design and testing facility in Vilnius, expansion into the US market and further improvements to its computational enzyme engineering platform.
Biomatter develops a computational platform that enables companies to design custom enzymes for specific chemical reactions and industrial applications. Its technology combines computational modelling with laboratory testing to develop enzymes with properties tailored to customer requirements, reducing development timelines that traditionally can extend from several months to years.
The company serves enterprise customers across Europe, the United States and Japan, including AstraZeneca, BASF, Sanofi and Tereos. Its technology has also been incorporated into commercial products, including an enzyme developed in collaboration with Thermo Fisher Scientific for molecular biology and mRNA research applications.
The new funding will support Biomatter’s plans to establish a 2,000-square-metre enzyme design and testing facility in Vilnius, scheduled to open in 2027. The company aims to use the facility and continued technology development to reduce enzyme design timelines from weeks to days.
Biomatter Secures $18M Series A Funding Led by Astanor
Biomatter’s $18 million Series A funding round was led by Astanor, with participation from existing investors UVC Partners, Inventure and Metaplanet.
The round was oversubscribed, indicating that investor demand exceeded the amount of capital the company initially sought to raise. However, Biomatter has not disclosed the original fundraising target or the level of investor demand.
The investment will support three main priorities: expanding its enzyme design and testing infrastructure, developing its computational platform and strengthening commercial operations in the United States.
A significant portion of the company’s expansion strategy involves establishing a new facility in Vilnius to bring more laboratory testing and development activities in-house.
Biomatter also plans to expand its proprietary dataset of experimentally characterised enzymes, which supports the computational models used to design new enzyme candidates.
The company has not disclosed its valuation following the Series A round, cumulative funding raised to date or the ownership stakes acquired by participating investors.
Biomatter Uses AI to Design Custom Enzymes for Industrial Applications
Biomatter develops computational technology that enables companies to create enzymes tailored to specific chemical reactions and operating conditions.
Enzymes are biological catalysts that accelerate chemical reactions and are widely used in pharmaceutical manufacturing, diagnostics, agriculture and industrial biotechnology.
Conventional enzyme development often begins with naturally occurring enzymes, which researchers modify to improve their performance or adapt them to a particular application.
However, naturally occurring enzymes may not have the properties required for specialized industrial processes. Developing suitable alternatives can involve extensive laboratory experimentation, making the process time-consuming and technically complex.
Biomatter approaches enzyme engineering by focusing on the chemistry required for a particular reaction. Its computational platform is designed to generate enzyme candidates suited to those requirements rather than relying exclusively on modifications to existing natural enzymes.
The company combines computational design with laboratory testing to evaluate enzyme performance and refine its models.
According to Biomatter, this approach has reduced its enzyme development process to weeks, compared with the months or years that conventional methods can require.
Biomatter Combines Computational Models With Experimental Enzyme Data
A central component of Biomatter’s technology is its proprietary dataset of experimentally characterised enzymes.
The company uses this dataset to support computational models that predict and design enzymes with properties suited to specific chemical reactions.
Each enzyme development programme generates additional experimental information, which can be incorporated into the dataset to improve subsequent design efforts.
This creates a feedback process in which computational predictions are tested in the laboratory and the resulting observations inform future enzyme designs.
By connecting computational modelling with experimental validation, Biomatter aims to reduce the number of development cycles required to identify enzymes suitable for commercial applications.
The approach is intended to improve the efficiency of enzyme engineering, particularly for chemical reactions where existing natural enzymes are unsuitable or unavailable.
Biomatter has not disclosed the size of its proprietary dataset, independent benchmarks of its design accuracy or the percentage of enzyme candidates that successfully meet customer requirements.
Biomatter Works With AstraZeneca, BASF, Sanofi and Tereos
Biomatter has developed custom enzymes for enterprise customers across Europe, the United States and Japan.
Its reported customers include AstraZeneca, BASF, Sanofi and Tereos, demonstrating applications across pharmaceutical, chemical and industrial biotechnology sectors.
Different industries require enzymes with specific properties, including stability, selectivity and compatibility with particular manufacturing conditions.
In pharmaceutical applications, enzymes can support chemical synthesis and the production of complex biological materials. In industrial biotechnology, they can enable specialized reactions used in manufacturing processes.
Biomatter’s platform is designed to address these requirements by developing enzymes around the chemical reactions customers need to perform.
The company has not disclosed the commercial value of its customer contracts, the number of enzyme development programmes completed or the revenue generated from its enterprise partnerships.
Nevertheless, its work with established international companies provides examples of how its computational enzyme design technology is being applied beyond laboratory research.
Biomatter Develops Enzyme With Thermo Fisher Scientific
Biomatter’s technology has also been used in commercial products, including an enzyme developed in collaboration with Thermo Fisher Scientific.
The enzyme was designed to improve stability in molecular biology and mRNA research applications.
Enzyme stability is an important consideration in laboratory and biotechnology processes because enzymes must maintain their functionality under the conditions required for a particular application.
By designing enzymes with targeted properties, Biomatter aims to address limitations that may affect the performance of existing products.
The collaboration with Thermo Fisher Scientific represents an example of Biomatter’s technology being incorporated into a commercially available application.
However, the company has not disclosed the product’s sales performance, the financial terms of the collaboration or independently verified comparisons with competing enzymes.
Biomatter Designs Methylase for mRNA Vaccine Manufacturing
Another application of Biomatter’s technology involves the development of a methylase enzyme intended for mRNA vaccine manufacturing.
According to the company, the enzyme can perform its intended reaction without S-adenosylmethionine (SAM), an expensive additive required by naturally occurring methylases.
SAM commonly serves as a methyl-group donor in enzymatic methylation reactions. Biomatter’s reported development demonstrates its approach to designing enzymes that can operate through alternative chemical mechanisms.
The company describes the enzyme as enabling a chemical reaction not found in nature.
If successfully implemented in relevant manufacturing processes, such technology could reduce dependence on certain costly inputs and create additional options for biotechnology production.
However, Biomatter has not disclosed the commercial deployment status of the methylase, independently verified production cost reductions or regulatory approvals associated with its use in vaccine manufacturing.
The development illustrates the company’s focus on designing enzymes for specific chemical requirements rather than limiting its work to naturally occurring enzyme functions.
Biomatter Plans 2,000-Square-Metre Enzyme Facility in Vilnius by 2027
Biomatter plans to establish a 2,000-square-metre enzyme design and testing facility in Vilnius, Lithuania, with an expected opening in 2027.
The facility will support the company’s efforts to bring more enzyme development and laboratory testing activities in-house.
By integrating computational design with expanded experimental capabilities, Biomatter aims to reduce the time required to develop custom enzymes.
The company currently reports development timelines measured in weeks and intends to shorten this process to days through its planned infrastructure and technology improvements.
The facility is expected to strengthen Biomatter’s ability to conduct testing, generate experimental data and support a larger number of customer development programmes.
Additional laboratory capacity could also contribute to the expansion of its proprietary enzyme dataset, supporting improvements to its computational platform.
Biomatter has not disclosed the construction cost of the facility, its planned workforce capacity or the number of enzyme development projects it will be able to support annually.
Biomatter Targets US Expansion and Faster Enzyme Commercialisation
Alongside its investment in research infrastructure, Biomatter plans to expand its commercial team and strengthen its presence in the United States.
The company already works with enterprise customers across Europe, the US and Japan, and the new investment will support its efforts to increase commercial adoption of its custom enzyme design services.
Biomatter’s long-term objective is to make custom enzyme development more accessible to companies that require specialized chemical reactions.
Laurynas Karpus, CEO and Co-founder of Biomatter, said the company’s goal is to make ordering a custom enzyme as straightforward as purchasing an existing catalogue product, including for reactions that currently lack suitable enzymes.
Achieving this objective will require continued improvements in computational design, laboratory validation and the efficiency of enzyme development workflows.
The company’s planned Vilnius facility and expanding proprietary dataset are intended to support this strategy.
Biomatter has not announced specific US hiring targets, new office locations or a timetable for entering additional international markets.
Biomatter Raises $18M to Accelerate AI-Driven Enzyme Engineering
Biomatter’s $18 million Series A funding round marks a new stage in the company’s development as it expands its AI-powered enzyme engineering platform.
Led by Astanor, with participation from UVC Partners, Inventure and Metaplanet, the oversubscribed financing will support the establishment of a 2,000-square-metre facility in Vilnius, continued technology development and commercial expansion in the United States.
Biomatter combines computational modelling with laboratory testing to design custom enzymes for pharmaceutical, diagnostic, agricultural and industrial biotechnology applications.
Its customers include AstraZeneca, BASF, Sanofi and Tereos, while its technology has also been incorporated into commercial products developed with Thermo Fisher Scientific.
With the new investment, the company aims to shorten enzyme development timelines from weeks to days and make specialized enzyme design more accessible to businesses requiring chemical reactions that conventional enzyme engineering methods struggle to support.
-
Euro Startups1 week agoDenmark-based HealthTech Startup Aisel Health Raises €1.7M Pre-Seed to Expand AI Psychiatry Platform Into the UK
-
Euro Startups1 week agoNetherlands-Based HealthTech Startup Blue Health Intelligence Raises €3.4M to Expand Preventive Healthcare Services Across Europe
-
MENA Startups1 week agoSaudi Venture Studio Persona Raises $630K Pre-Seed Funding Led by Upturn to Expand Eight Consumer Brands Across the GCC
-
MENA Startups1 week agoSaudi AI-Powered SalesTech Startup Mawsool Secures Pre-Seed Funding From Angel Investors to Expand Lead Generation Platform Across MENA
-
MENA Startups1 week agoOman-Based ClimateTech Startup 44.01 Secures Strategic Investment From Global Building Materials Company Holcim to Scale Carbon Mineralization Technology
-
MENA Startups1 week agoUAE-Based FinTech Startup Wafr Raises Pre-Seed Funding and Launches WafrChain, a Blockchain Platform to Expand Shariah-Compliant Financial Services Globally
-
Asia Startups1 week agoIndian Food Startup Harajuku Tokyo Cafe Raises $3M Pre-Series A Funding to Expand Bakery and Packaged Food Operations
-
MENA Startups1 week agoEgypt-Based Technology Company X-GEN Targets $92M in Investments Over Three Years to Localize Drone and Robotics Manufacturing and Expand Regionally

You must be logged in to post a comment Login